Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer?
Angela Collarino,Vanessa Feudo,Tina Pasciuto,Anita Florit,Elisabeth Pfaehler,Marco de Summa,Nicolò Bizzarri,Salvatore Annunziata,Gian Franco Zannoni,Lioe-Fee de Geus-Oei,Gabriella Ferrandina,Maria Antonietta Gambacorta,Giovanni Scambia,Ronald Boellaard,Evis Sala,Vittoria Rufini,Floris Hp van Velden,Floris HP van Velden
DOI: https://doi.org/10.2967/jnumed.123.267044
2024-03-28
Journal of Nuclear Medicine
Abstract:This study investigated whether radiomic features extracted from pretreatment [<sup>18</sup>F]FDG PET could improve the prediction of both histopathologic tumor response and survival in patients with locally advanced cervical cancer (LACC) treated with neoadjuvant chemoradiotherapy followed by surgery compared with conventional PET parameters and histopathologic features. <b>Methods:</b> The medical records of all consecutive patients with LACC referred between July 2010 and July 2016 were reviewed. [<sup>18</sup>F]FDG PET/CT was performed before neoadjuvant chemoradiotherapy. Radiomic features were extracted from the primary tumor volumes delineated semiautomatically on the PET images and reduced by factor analysis. A receiver-operating-characteristic analysis was performed, and conventional and radiomic features were dichotomized with Liu's method according to pathologic response (pR) and cancer-specific death. According to the study protocol, only areas under the curve of more than 0.70 were selected for further analysis, including logistic regression analysis for response prediction and Cox regression analysis for survival prediction. <b>Results:</b> A total of 195 patients fulfilled the inclusion criteria. At pathologic evaluation after surgery, 131 patients (67.2%) had no or microscopic (≤3 mm) residual tumor (pR0 or pR1, respectively); 64 patients (32.8%) had macroscopic residual tumor (>3 mm, pR2). With a median follow-up of 76.0 mo (95% CI, 70.7-78.7 mo), 31.3% of patients had recurrence or progression and 20.0% died of the disease. Among conventional PET parameters, SUV<sub>mean</sub> significantly differed between pathologic responders and nonresponders. Among radiomic features, 1 shape and 3 textural features significantly differed between pathologic responders and nonresponders. Three radiomic features significantly differed between presence and absence of recurrence or progression and between presence and absence of cancer-specific death. Areas under the curve were less than 0.70 for all parameters; thus, univariate and multivariate regression analyses were not performed. <b>Conclusion:</b> In a large series of patients with LACC treated with neoadjuvant chemoradiotherapy followed by surgery, PET radiomic features could not predict histopathologic tumor response and survival. It is crucial to further explore the biologic mechanism underlying imaging-derived parameters and plan a large, prospective, multicenter study with standardized protocols for all phases of the process of radiomic analysis to validate radiomics before its use in clinical routine.
radiology, nuclear medicine & medical imaging